A clinical perspective of canagliflozin in the management of type 2 diabetes mellitus.

Nardolillo, AnneMarie; Kane, Michael P; Busch, Robert S; Watsky, Jay; Hamilton, Robert A

Nardolillo, AnneMarie; Kane, Michael P; Busch, Robert S; Watsky, Jay; Hamilton, Robert A.

Afiliação

Nardolillo A; Albany College of Pharmacy and Health Sciences, Albany, NY.
Kane MP; Albany College of Pharmacy and Health Sciences, Albany, NY.
Busch RS; The Endocrine Group, LLP, Albany, NY.
Watsky J; The Endocrine Group, LLP, Albany, NY.
Hamilton RA; Albany College of Pharmacy and Health Sciences-Vermont Campus, Colchester, VT.

Clin Med Insights Endocrinol Diabetes ; 7: 25-30, 2014.

Article em En | MEDLINE | ID: mdl-25288892

Palavras-chave

Invokana; SGLT-2 inhibitor; canagliflozin; type 2 diabetes mellitus

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Revista: Clin Med Insights Endocrinol Diabetes Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google